Amicus Therapeutics CEO Executes Significant Stock Transactions Amid Acquisition Developments
Campbell Bradley L., the President and CEO of Amicus Therapeutics, completed a sale of 75,000 shares on January 20, 2026, generating approximately $1.07 million. Alongside this, he exercised options to acquire an equal number of shares. This insider activity coincides with a strong market performance for Amicus shares and the announcement of an all…